| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Minocycline binds the bacterial 30S ribosomal subunit to inhibit protein synthesis and also modulates p38 MAPK, PI3K/Akt, matrix metalloproteinases, caspase-1/3, microglial activation, and 5-lipoxygenase, contributing to its anti-inflammatory and neuroprotective effects.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, minocycline inhibits proliferation of OVCAR-3, SKOV-3, and A2780 ovarian cancer cells with IC50 values of 62.0, 56.1, and 59.5 μM, and it suppresses microglial activation and inflammatory mediator production by inhibiting p38 MAPK. |
| ln Vivo |
In vivo, minocycline exhibits neuroprotection in spinal cord injury and neurodegenerative disease models through anti-inflammatory, antioxidant, and anti-apoptotic mechanisms, and it is clinically available as an antibiotic and anti-inflammatory agent.
|
| Enzyme Assay |
Noncellular binding assays incubate bacterial 30S ribosomal subunits or recombinant p38 MAPK with radiolabeled or fluorescent ligands and increasing concentrations of minocycline-d6; Ki or IC50 values are derived to quantify ribosomal and kinase interactions.
|
| Cell Assay |
Cellular assays use microglia, neurons, or cancer cell lines treated with minocycline-d6; p38 MAPK and Akt phosphorylation are measured by immunoblotting, cytokine release by ELISA, and cell viability by MTT, with ribosomal protein synthesis assessed by [35S]methionine incorporation.
|
| Animal Protocol |
Animal protocols administer minocycline-d6 orally or intraperitoneally to rodents in spinal cord injury or neuroinflammation models at doses of 10–100 mg/kg; inflammatory markers, microglial activation, and functional recovery are measured, and plasma and tissue concentrations are quantified by LC-MS/MS.
|
| References |
| Molecular Formula |
C23H33N3O3
|
|---|---|
| Molecular Weight |
405.563396215439
|
| Exact Mass |
463.222
|
| CAS # |
1036070-10-6
|
| Related CAS # |
Minocycline;10118-90-8
|
| PubChem CID |
163285325
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
803.3±65.0 °C at 760 mmHg
|
| Flash Point |
439.6±34.3 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.718
|
| LogP |
-0.65
|
| tPSA |
165
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
35
|
| Complexity |
971
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1(=O)[C@@]2([H])[C@]([H])(C[C@]3([H])C(C2)C(=O)C2C(=C(N(C)C)C=CC2)C3)[C@@H](N(C([2H])([2H])[2H])C([2H])([2H])[2H])CC1C(N)=O
|
| InChi Key |
WFRONWCNHNRGLC-ZPEOJIAISA-N
|
| InChi Code |
InChI=1S/C23H27N3O7.2ClH/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28;;/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32);2*1H/t9-,11-,17-,23-;;/m0../s1/i1D3,2D3;;
|
| Chemical Name |
(4S,4aS,5aR,12aR)-7-[bis(trideuteriomethyl)amino]-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4657 mL | 12.3286 mL | 24.6573 mL | |
| 5 mM | 0.4931 mL | 2.4657 mL | 4.9315 mL | |
| 10 mM | 0.2466 mL | 1.2329 mL | 2.4657 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.